|  |
| --- |
| Billing, Reimbursement, and Access for Remdesivir |
| **Outpatient remdesivir administration**   * The Centers for Medicare and Medicaid Services (CMS) approved Healthcare Common Procedure Coding System (HCPCS) Code **J0248**   + 1mg billing increment, available for all payers, services on or after 12/23/2021 * American Medical Association (AMA) Current Procedural Terminology (CPT) codes  |  |  | | --- | --- | | * 96365   IV infusion, for therapy, prophylaxis or diagnosis up to 1 hour | * 96367   IV infusion, for therapy, prophylaxis, or diagnosis, additional sequential infusion of a new drug/substance, up to 1 hour | | * 96366   IV infusion, for therapy, prophylaxis, or diagnosis, each additional hour | * 96369   IV infusion, for therapy, prophylaxis, or diagnosis; concurrent infusion |   **Inpatient remdesivir administration**   * Medical centers/facilities should contact their respective [Medicare Administrative Contractor (MAC)](https://www.cms.gov/MAC-info) for specific billing instructions * CMS payment enhancement available under New COVID-19 Treatments Add-on Payment (NCTAP) program for remdesivir (and other COVID-19 therapies)   + NCTAP helps to mitigate financial disincentives for medical centers/hospitals to provide new COVID-19 therapeutics   + Effective from 11/2/2020 until 9/30/2023 of the COVID-19 public health emergency   + NCTAP claims eligibility for 20% add-on payment under section 3710 of the Coronavirus Aid, Relief, and Economic Securities (CARES) Act has EXPIRED 5/11/2023.   + NCTAP is equal to the lesser of 65% of operating outlier threshold for the claim OR 65% of the amount by which the costs exceed the standard diagnosis-related group (DRG) payment   + More information about NCTAP [here](https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap) * Medicare DRG enhancement   + Section 3710 of the CARES Act allowed for an increase in the weighting factor for a DRG by 20% for an individual diagnosed with COVID-19 and discharged during the public health emergency time period, this however EXPIRED 5/11/2023.   + A positive COVID-19 test is required for claims to be eligible   Additional information regarding Coding and Reimbursement for remdesivir is available [here](https://www.vekluryhcp.com/downloads/Coding_and_Reimbursement_information.pdf)  Assistance for access to remdesivir is available through the [Gilead Advancing Access](https://www.vekluryhcp.com/access/) program   * Offers assistance with co-pay information, coding/reimbursement, verification * Contact: 1-800-226-2056 (option 4); M-F 0900-2000 EST |